Exosome-Encapsulated CRISPR Delivery for Inner Ear Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for sensorineural hearing loss (SNHL) face challenges such as poor delivery to the inner ear due to the blood-labyrinth barrier, leading to inefficient and non-specific targeting, and they often result in toxicity and immunogenicity.
Innovation Solution
The use of CRISPR/Cas endonuclease compositions, specifically Cas9, encapsulated within extracellular vesicles like exosomes, which deliver guide RNAs and template nucleic acids to target and correct mutations in the MYO7A gene, facilitating homology-directed repair and overcoming the barriers to achieve targeted gene therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If intratympanic injection or hydrogel delivery is used to deliver therapeutics into the ear, then the delivery method is simple and non-invasive, but the penetration of therapeutics through the blood-labyrinth barrier to the inner ear is poor
Solution Approach 1:
The patent uses exosomes as intermediary carriers to transport CRISPR/Cas9 gene editing components across the blood-labyrinth barrier. These exosomes are engineered to specifically target inner ear hair cells, enabling efficient delivery of therapeutic nucleic acids while maintaining non-invasive administration routes.
Solution Approach 2:
The patent modifies the physical and chemical parameters of the delivery system by using extracellular vesicles with specific surface properties and sizes that enable them to cross the blood-labyrinth barrier. The exosomes are engineered with specific membrane proteins and surface charges that facilitate barrier penetration and cellular uptake.
2Reliability
If viral vectors are used for gene delivery, then transgene expression can be achieved, but toxicity and immunogenicity increase
Solution Approach 1:
The patent employs non-viral exosome-based delivery systems that are biodegradable and transient, avoiding the persistent immunogenicity associated with viral vectors. The exosomes deliver their cargo and are naturally degraded by cellular processes, minimizing long-term toxicity and immune responses.
Solution Approach 2:
The patent uses exosomes as a biocompatible intermediary that protects the CRISPR/Cas9 components from degradation and immune detection while delivering them to target cells. This exosome-mediated delivery avoids direct exposure to immunogenic viral proteins while achieving efficient gene editing.
3Device complexity
If conventional delivery methods are used, then the delivery system is simple, but targeted delivery to inner ear hair cells is insufficient
Solution Approach 1:
The patent engineering exosomes with location-specific properties, including surface proteins and ligands that are specifically expressed on inner ear hair cells. This localized targeting ensures that the gene editing components are delivered precisely to the intended cell type while maintaining relatively simple overall system design.
Solution Approach 2:
The patent creates a multi-functional exosome delivery system that combines barrier penetration, cellular targeting, and protected cargo delivery in a single platform. The exosomes serve multiple functions simultaneously: crossing the blood-labyrinth barrier, targeting specific hair cells, and protecting the CRISPR/Cas9 components during transport.
Data Source
AI summary
Provided herein are compositions and methods useful in the treatment of hearing loss diseases, such as by correction of mutations in genes associated with hearing.